See the DrugPatentWatch profile for lurbinectedin

Lurbinectedin, a novel anticancer drug, has been associated with a range of side effects [1]. However, the frequency of monitoring these side effects through lab tests is not explicitly stated in the available information.

The prescribing information for lurbinectedin does mention that regular monitoring of blood cell counts is necessary due to the risk of myelosuppression, a condition where the body's ability to make blood cells is decreased [2]. This monitoring is typically done through complete blood count (CBC) tests.

Moreover, liver function should be assessed before each dose, as lurbinectedin can cause increased levels of liver enzymes [2]. This is usually done through liver function tests.

However, the specific frequency of these tests is not provided in the prescribing information. It is likely that the frequency would be determined by the treating physician, based on the patient's individual response to treatment and the severity of any side effects.

In conclusion, while the side effects of lurbinectedin are known to require monitoring, the frequency of these tests is not explicitly stated in the available information. It is likely that the frequency of lab tests would be determined by the treating physician, based on the individual patient's needs.

Sources:
[1] "Lurbinectedin." DrugPatentWatch, www.drugpatentwatch.com/drugs/lurbinectedin.
[2] "Zepzelca (lurbinectedin) tablets for oral use prescribing information." PharmaMar USA Inc., Jan 2021, www.accessdata.fda.gov/drugsatfda_docs/label/2021/213537s000lbl.pdf.